Our proprietary platform technology enables for the development of infusible therapeutics that target harmful antibodies in autoimmune diseases, transplant rejection or drug neutralization of biotherapeutics. Ablevia’s selective antibody depletion compounds can be readily adapted to target undesired antibodies in rare conditions with unmet clinical needs. The company was founded in 2018 at the Vienna Biocenter Campus and focusses on preclinical research and development.
Ablevia is reaching out for cooperation programs with strong partners that need to address undesired antibodies in preclinical and clinical settings.
Our proprietary platform technology enables for the development of infusible therapeutics that target harmful antibodies in autoimmune diseases, transplant rejection or drug neutralization of biotherapeutics. Ablevia’s selective antibody depletion compounds can be readily adapted to target undesired antibodies in rare conditions with unmet clinical needs. The company was founded in 2018 at the Vienna Biocenter Campus and focusses on preclinical research and development.
Ablevia is reaching out for cooperation programs with strong partners that need to address undesired antibodies in preclinical and clinical settings.
[(c) stock.adobe.com]
(c) 2019 Ablevia biotech GmbH, Vienna Biocenter, Österreich
selective antibody removal therapeutics
